Vaccinology in the third millennium: Scientific and social challenges

Current Opinion in Virology

Volumn 17, Issue , 2016, Pages 116-125

  Poland, Gregory A ^a   Whitaker, Jennifer A ^a   Poland, Caroline M ^b   Ovsyannikova, Inna G ^a   Kennedy, Richard B ^a  

^a MAYO CLINIC   (United States)

^b TAYLOR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR; VIRUS VACCINE; INFLUENZA VACCINE; VACCINE;

ADAPTIVE IMMUNITY; CHIKUNGUNYA; EBOLA HEMORRHAGIC FEVER; HUMAN; IMMUNOGENETICS; IMMUNOGENICITY; INFLUENZA; INNATE IMMUNITY; MEASLES; MUMPS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VACCINATION; VACCINE FAILURE; VACCINOLOGY; VIRUS INFECTION; WEST NILE FEVER; ZIKA VIRUS INFECTION; COMMUNICABLE DISEASE CONTROL; DRUG DESIGN; DRUG DEVELOPMENT; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; VACCINATION REFUSAL; VACCINE IMMUNOGENICITY; ZIKA VIRUS;

COMMUNICABLE DISEASE CONTROL; DRUG DESIGN; DRUG DISCOVERY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MEASLES; VACCINATION; VACCINATION REFUSAL; VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84962197773     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.03.003     Document Type: Review

References (111)

1. Centers for Disease Control and Prevention MMWR 48 1999 621 629
2. RTS,S Clinical Trials Partnership Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial Lancet 386 2015 31 45
3. World Health Organization HIV/AIDS Fact Sheet No. 360 2015 http://www.who.int/mediacentre/factsheets/fs360/en/ [accessed 12.02.16]
4. World Health Organization Ebola Situation Report 2015 http://apps.who.int/iris/bitstream/10665/183400/1/Ebolasitrep-26Aug2015-eng.pdf?ua=1 [accessed 12.02.16]
5. A.M. Henao-Restrepo, I.M. Longini, M. Egger, N.E. Dean, W.J. Edmunds, A. Camacho, M.W. Carroll, M. Doumbia, B. Draguez, S. Duraffour, and et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial Lancet 386 2015 857 866
6. A. Marzi, S.J. Robertson, E. Haddock, F. Feldmann, P.W. Hanley, D.P. Scott, J.E. Strong, G. Kobinger, S.M. Best, and H. Feldmann EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain Science 349 2015 739 742
7. U.N. Sarwar, P. Costner, M.E. Enama, N. Berkowitz, Z. Hu, C.S. Hendel, S. Sitar, S. Plummer, S. Mulangu, R.T. Bailer, and et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial J Infect Dis 211 2015 549 557
8. H. Kibuuka, N.M. Berkowitz, M. Millard, M.E. Enama, A. Tindikahwa, A.B. Sekiziyivu, P. Costner, S. Sitar, D. Glover, Z. Hu, and et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial Lancet 385 2015 1545 1554
9. EçSRVT Consortium The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola BMJ 351 2015 h3740
10. S.A. Plotkin, A.A. Mahmoud, and J. Farrar Establishing a global vaccine-development fund N Engl J Med 373 2015 297 300
11. K. Cardell, B. Akerlind, M. Sallberg, and A. Fryden Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine J Infect Dis 198 2008 299 304
12. D.M. Skowronski, S.A. Tweed, and G. De Serres Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 197 2008 490 502
13. D.E. Michalik, S.P. Steinberg, P.S. LaRussa, K.M. Edwards, P.F. Wright, A.M. Arvin, H.A. Gans, and A.A. Gershon Primary vaccine failure after 1 dose of varicella vaccine in healthy children J Infect Dis 197 2008 944 949
14. J. McVernon, N. Andrews, M.P. Slack, and M.E. Ramsay Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis Lancet 361 2003 1521 1523
15. G.A. Poland, I.G. Ovsyannikova, R.M. Jacobson, and D.I. Smith Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics Clin Pharmacol Ther 82 2007 653 664
16. I.G. Ovsyannikova, N. Dhiman, R.M. Jacobson, and G.A. Poland Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines Exp Rev Vaccines 5 2006 33 43
17. H.D. Clifford, C.M. Hayden, S.K. Khoo, D. Naniche, I.M. Mandomando, G. Zhang, P. Richmond, and P.N. Le Souef Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique Vaccine 30 2012 6180 6185
18. C.M. Gelder, R. Lambkin, K.W. Hart, D. Fleming, O.M. Williams, M. Bunce, K.I. Welsh, S.E. Marshall, and J. Oxford Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine J Infect Dis 185 2002 114 117
19. S. Davila, F.E. Froeling, A. Tan, C. Bonnard, G.J. Boland, H. Snippe, M.L. Hibberd, and M. Seielstad New genetic associations detected in a host response study to hepatitis B vaccine Genes Immunity 11 2010 232 238
20. S.A. Plotkin The pertussis problem Clin Infect Dis 58 2014 830 833
21. E. Chiappini, A. Stival, L. Galli, and M. de Martino Pertussis re-emergence in the post-vaccination era BMC Infect Dis 13 2013 151
22. K.E. Schmader, M.J. Levin, J.W. Gnann Jr., S.A. McNeil, T. Vesikari, R.F. Betts, S. Keay, J.E. Stek, N.D. Bundick, S.C. Su, and et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years Clin Infect Dis 54 2012 922 928
23. M.N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, L.D. Gelb, R.D. Arbeit, M.S. Simberkoff, A.A. Gershon, L.E. Davis, and et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
24. R. Chlibek, J.M. Bayas, H. Collins, M.L. de la Pinta, E. Ledent, J.F. Mols, and T.C. Heineman Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age J Infect Dis 208 2013 1953 1961
25. R. Chlibek, J. Smetana, K. Pauksens, L. Rombo, J.A. Van den Hoek, J.H. Richardus, G. Plassmann, T.F. Schwarz, E. Ledent, and T.C. Heineman Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study Vaccine 32 2014 1745 1753
26. S.R. Hadinegoro, J.L. Arredondo-Garcia, M.R. Capeding, C. Deseda, T. Chotpitayasunondh, R. Dietze, H.I. Muhammad Ismail, H. Reynales, K. Limkittikul, D.M. Rivera-Medina, and et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease N Engl J Med 373 2015 1195 1206
27. G. Galli, K. Hancock, K. Hoschler, J. DeVos, M. Praus, M. Bardelli, C. Malzone, F. Castellino, C. Gentile, T. McNally, and et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine Proc Natl Acad Sci U S A 106 2009 7962 7967
28. F. Ansaldi, S. Bacilieri, P. Durando, L. Sticchi, L. Valle, E. Montomoli, G. Icardi, R. Gasparini, and P. Crovari Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses Vaccine 26 2008 1525 1529
29. S.E. Frey, M.R. Reyes, H. Reynales, N.N. Bermal, U. Nicolay, V. Narasimhan, E. Forleo-Neto, and A.K. Arora Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects Vaccine 32 2014 5027 5034
30. C.A. DiazGranados, A.J. Dunning, M. Kimmel, D. Kirby, J. Treanor, A. Collins, R. Pollak, J. Christoff, J. Earl, V. Landolfi, and et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults N Engl J Med 371 2014 635 645
31. J. Montplaisir, D. Petit, M.J. Quinn, M. Ouakki, G. Deceuninck, A. Desautels, E. Mignot, and P. De Wals Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec PLOS ONE 9 2014 e108489
32. G.A. Poland, R.B. Kennedy, B.A. McKinney, I.G. Ovsyannikova, N.D. Lambert, R.M. Jacobson, and A.L. Oberg Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century Semin Immunol 25 2013 89 103
33. J.F. Anders, R.M. Jacobson, G.A. Poland, S.J. Jacobsen, and P.C. Wollan Secondary failure rates of measles vaccines: a metaanalysis of published studies Pediatr Infect Dis J 15 1996 62 66
34. G.A. Poland, R.M. Jacobson, A.M. Thampy, S.A. Colbourne, P.C. Wollan, J.J. Lipsky, and S.J. Jacobson Measles re-immunization in children seronegative after initial immunization J Am Med Assoc 277 1997 1156 1158
35. K. Cardell, A. Fryden, and B. Normann Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise Scand J Infect Dis 31 1999 197 200
36. C.A. Alper, M.S. Kruskall, D. Marcus-Bagley, D.E. Craven, A.J. Katz, S.J. Brink, J.L. Dienstag, Z. Awdeh, and E.J. Yunis Genetic prediction of nonresponse to hepatitis B vaccine N Engl J Med 321 1989 708 712
37. C. Hannoun, F. Megas, and J. Piercy Immunogenicity and protective efficacy of influenza vaccination Virus Res 103 2004 133 138
38. J.S. Marks, and T.J. Halpin Guillain-Barre syndrome in recipients of A/New Jersey influenza vaccine J Am Med Assoc 243 1980 2490 2494
39. P. Haber, F. DeStefano, F.J. Angulo, J. Iskander, S.V. Shadomy, E. Weintraub, and R.T. Chen Guillain-Barre syndrome following influenza vaccination J Am Med Assoc 292 2004 2478 2481
40. L.B. Schonberger, D.J. Bregman, J.Z. Sullivan-Bolyai, R.A. Keenlyside, D.W. Ziegler, H.F. Retailliau, D.L. Eddins, and J.A. Bryan Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977 Am J Epidemiol 110 1979 105 123
41. H. Nohynek, J. Jokinen, M. Partinen, O. Vaarala, T. Kirjavainen, J. Sundman, S.L. Himanen, C. Hublin, I. Julkunen, P. Olsen, and et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland PLoS ONE 7 2012 e33536
42. M. Partinen, O. Saarenpaa-Heikkila, I. Ilveskoski, C. Hublin, M. Linna, P. Olsen, P. Nokelainen, R. Alen, T. Wallden, M. Espo, and et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland PLoS ONE 7 2012 e33723
43. C.F. Santillan Salas, S. Mehra, M.R. Pardo Crespo, and Y.J. Juhn Asthma and severity of 2009 novel H1N1 influenza: a population-based case-control study J Asthma 50 2013 1069 1076
44. D.R. Freitas, E. Moura, G. Araujo, A. Cardoso, P. Scheidt, E. Ferraz, G. Madalosso, R.T. Chen, and D.L. Hatch Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil Vaccine 31 2013 950 954
45. G.L. Lawrence, M.A. Burgess, and R.B. Kass Age-related risk of adverse events following yellow fever vaccination in Australia Commun Dis Intell Q Rep 28 2004 244 248
46. M.K. Patel, T.K. Patel, and C.B. Tripathi Diphtheria, pertussis (whooping cough), and tetanus vaccine induced recurrent seizures and acute encephalopathy in a pediatric patient: possibly due to pertussis fraction J Pharmacol Pharmacother 3 2012 71 73
47. W.E. Barlow, R. Davis, J.W. Glasser, P.H. Rhodes, R.S. Thompson, J.P. Mullooly, S.B. Black, H.R. Shinefield, J.I. Ward, M. Marcy, and et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine N Engl J Med 345 2001 656 661
48. M. Higashigawa, K. Maegawa, H. Honma, A. Yoshino, K. Onozato, Y. Nashida, T. Fujiwara, and M. Inoue Vaccine-associated paralytic poliomyelitis in an infant with perianal abscesses J Infect Chemother 16 2010 356 359
49. G.A. Poland, I.G. Ovsyannikova, and R.M. Jacobson Adversomics: the emerging field of vaccine adverse event immunogenetics Pediatr Infect Dis J 28 2009 431 432
50. J.A. Whitaker, I.G. Ovsyannikova, and G.A. Poland Adversomics: a new paradigm for vaccine safety and design Exp Rev Vaccines 2015 1 13
51. W.H. Chen, B.F. Kozlovsky, R.B. Effros, B. Grubeck-Loebenstein, R. Edelman, and M.B. Sztein Vaccination in the elderly: an immunological perspective Trends Immunol 30 2009 351 359
52. R.B. Effros Problems and solutions to the development of vaccines in the elderly Immunol Allergy Clin North Am 23 2003 41 55
53. B. Grubeck-Loebenstein, B.S. Della, A.M. Iorio, J.P. Michel, G. Pawelec, and R. Solana Immunosenescence and vaccine failure in the elderly Aging Clin Exp Res 21 2009 201 209
54. C.M. Poland, and E.K. Brunson The need for a multi-disciplinary perspective on vaccine hesitancy and acceptance Vaccine 33 2015 277 279
55. C.M. Poland, and G.A. Poland Vaccine education spectrum disorder: the importance of incorporating psychological and cognitive models into vaccine education Vaccine 29 2011 6145 6148
56. C.M. Poland, and 1. Poland GA: Vaccination as a public health measure: challenges W.C. Cockerham, R. Dingwall, S.R. Quah, The Wiley-Blackwell Encyclopedia of Health, Illness, Behavior and Society 2014 Wiley-Blackwell
57. W.C. Koff, I.D. Gust, and S.A. Plotkin Toward a human vaccines project Nat Immunol 15 2014 589 592
58. W.C. Koff, D.R. Burton, P.R. Johnson, B.D. Walker, C.R. King, G.J. Nabel, R. Ahmed, M.K. Bhan, and S.A. Plotkin Accelerating next-generation vaccine development for global disease prevention Science 340 2013 1232910
59. T. Schenkelberg, M.P. Kieny, A.E. Bianco, and W.C. Koff Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop Exp Rev Vaccines 14 2015 629 636
60. Y.D. Mahnke, T.M. Brodie, F. Sallusto, M. Roederer, and E. Lugli The who's who of T-cell differentiation: human memory T-cell subsets Eur J Immunol 43 2013 2797 2809
61. J. Geginat, M. Paroni, S. Maglie, J.S. Alfen, I. Kastirr, P. Gruarin, M. De Simone, M. Pagani, and S. Abrignani Plasticity of human CD4 T cell subsets Front Immunol 5 2014 630
62. M. Durand, and E. Segura The known unknowns of the human dendritic cell network Front Immunol 6 2015 129
63. M. Merad, P. Sathe, J. Helft, J. Miller, and A. Mortha The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting Annu Rev Immunol 31 2013 563 604
64. E.C. Rosser, and C. Mauri Regulatory B cells: origin, phenotype, and function Immunity 42 2015 607 612
65. A. Iwasaki, and R. Medzhitov Control of adaptive immunity by the innate immune system Nat Immunol 16 2015 343 353
66. L.V. Hooper, D.R. Littman, and A.J. Macpherson Interactions between the microbiota and the immune system Science 336 2012 1268 1273
67. Y. Valdez, E.M. Brown, and B.B. Finlay Influence of the microbiota on vaccine effectiveness Trends Immunol 35 2014 526 537
68. B. Pulendran Systems vaccinology: probing humanity's diverse immune systems with vaccines Proc Natl Acad Sci U S A 111 2014 12300 12306
69. G. Obermoser, S. Presnell, K. Domico, H. Xu, Y. Wang, E. Anguiano, L. Thompson-Snipes, R. Ranganathan, B. Zeitner, A. Bjork, and et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines Immunity 38 2013 831 844
70. A.L. Oberg, R.B. Kennedy, P. Li, I.G. Ovsyannikova, and G.A. Poland Systems biology approaches to new vaccine development Curr Opin Immunol 23 2011 436 443
71. J.A. Reuter, D.V. Spacek, and M.P. Snyder High-throughput sequencing technologies Mol Cell 58 2015 586 597
72. Y. Wang, and N.E. Navin Advances and applications of single-cell sequencing technologies Mol Cell 58 2015 598 609
73. S.C. Bendall, G.P. Nolan, M. Roederer, and P.K. Chattopadhyay A deep profiler's guide to cytometry Trends Immunol 33 2012 323 332
74. O. Ornatsky, D. Bandura, V. Baranov, M. Nitz, M.A. Winnik, and S. Tanner Highly multiparametric analysis by mass cytometry J Immunol Methods 361 2010 1 20
75. Z.B. Bjornson, G.P. Nolan, and W.J. Fantl Single-cell mass cytometry for analysis of immune system functional states Curr Opin Immunol 25 2013 484 494
76. A.L. Oberg, B.A. McKinney, D.J. Schaid, V.S. Pankratz, R.B. Kennedy, and G.A. Poland Lessons learned in the analysis of high-dimensional data in vaccinomics Vaccine 2015 S0264-410X:00574-00575
77. H.I. Nakaya, and B. Pulendran Vaccinology in the era of high-throughput biology Philos Trans R Soc Lond B Biol Sci 370 2015
78. D.E. Zak, V.C. Tam, and A. Aderem Systems-level analysis of innate immunity Annu Rev Immunol 32 2014 547 577
79. R.N. Germain, M. Meier-Schellersheim, A. Nita-Lazar, and I.D. Fraser Systems biology in immunology: a computational modeling perspective Annu Rev Immunol 29 2011 527 585
80. A.G. de Brevern, J.P. Meyniel, C. Fairhead, C. Neuveglise, and A. Malpertuy Trends in IT innovation to build a next generation bioinformatics solution to manage and analyse biological big data produced by NGS technologies BioMed Res Int 2015 2015 904541
81. G.A. Poland, R.B. Kennedy, and I.G. Ovsyannikova Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 7 2011 e1002344
82. R.B. Kennedy, and G.A. Poland The top five "game changers" in vaccinology: toward rational and directed vaccine development OMICS 15 2011 533 537
83. G.A. Poland, I.G. Ovsyannikova, R.B. Kennedy, I.H. Haralambieva, and R.M. Jacobson Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections OMICS 15 2011 625 636
84. I.G. Ovsyannikova, and G.A. Poland Vaccinomics: current findings, challenges and novel approaches for vaccine development Am Assoc Pharm Sci 13 2011 438 444
85. I.H. Haralambieva, and G.A. Poland Vaccinomics, predictive vaccinology and the future of vaccine development Future Microbiol 5 2010 1757 1760
86. G.A. Poland, and A.L. Oberg Vaccinomics and bioinformatics: accelerants for the next golden age of vaccinology Vaccine 28 2010 3509 3510
87. G.A. Poland, R.M. Jacobson, and I.G. Ovsyannikova Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine and consumer culture and vaccinomics Vaccine 27 2009 3240 3244
88. G.A. Poland, I.G. Ovsyannikova, and R.M. Jacobson Personalized vaccines: the emerging field of vaccinomics Expert Opin Biol Ther 8 2008 1659 1667
89. J.S. Tsang Utilizing population variation, vaccination, and systems biology to study human immunology Trends Immunol 36 2015 479 493
90. F. Pappalardo, D. Flower, G. Russo, M. Pennisi, and S. Motta Computational modelling approaches to vaccinology Pharmacol Res 92 2015 40 45
91. M. Mooney, S. McWeeney, G. Canderan, and R.P. Sekaly A systems framework for vaccine design Curr Opin Immunol 25 2013 551 555
92. R.A. Gottschalk, A.J. Martins, V.H. Sjoelund, B.R. Angermann, B. Lin, and R.N. Germain Recent progress using systems biology approaches to better understand molecular mechanisms of immunity Semin Immunol 25 2013 201 208
93. T.R. Kollmann, O. Levy, R.R. Montgomery, and S. Goriely Innate immune function by toll-like receptors: distinct responses in newborns and the elderly Immunity 37 2012 771 783
94. O. Levy, S. Goriely, and T.R. Kollmann Immune response to vaccine adjuvants during the first year of life Vaccine 31 2013 2500 2505
95. D. Boraschi, and P. Italiani Immunosenescence and vaccine failure in the elderly: strategies for improving response Immunol Lett 162 2014 346 353
96. G.A. Poland, I.G. Ovsyannikova, R.B. Kennedy, N.D. Lambert, and J.L. Kirkland A systems biology approach to the effect of aging, immunosenescence and vaccine response Curr Opin Immunol 29C 2014 62 68
97. S.S. Duraisingham, N. Rouphael, M.M. Cavanagh, H.I. Nakaya, J.J. Goronzy, and B. Pulendran Systems biology of vaccination in the elderly Curr Top Microbiol Immunol 363 2013 117 142
98. C.C. Whiting, J. Siebert, A.M. Newman, H.W. Du, A.A. Alizadeh, J. Goronzy, C.M. Weyand, E. Krishnan, C.G. Fathman, and H.T. Maecker Large-scale and comprehensive immune profiling and functional analysis of normal human aging PLOS ONE 10 2015 e0133627
99. R. Banchereau, N. Baldwin, A.M. Cepika, S. Athale, Y. Xue, C.I. Yu, P. Metang, A. Cheruku, I. Berthier, I. Gayet, and et al. Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines Nat Commun 5 2014 5283
100. UNAIDS Fact sheet 2015 2016 http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet [accessed 12.02.16]
101. World Health Organization Global Tuberculosis Report 2015 2016 http://www.who.int/tb/publications/global-report/en/ [accessed 12.02.2016]
102. World Health Organization Malaria Fact Sheet 2016 http://www.who.int/mediacentre/factsheets/fs094/en/ [accessed 12.02.16]
103. World Health Organization Hepatitis C Fact Sheet No. 164 2015 http://www.who.int/mediacentre/factsheets/fs164/en/ [accessed 12.02.16]
104. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, and et al. The global distribution and burden of dengue Nature 496 2013 504 507
105. World Health Organization Ebola Situation Reports 2016 http://apps.who.int/ebola/ebola-situation-reports [accessed 12.02.16]
106. Centers for Disease Control and Prevention Marburg Hemorrhagic Fever 2014 http://www.cdc.gov/vhf/marburg/resources/outbreak-table.html [accessed 12.02.16]
107. Centers for Disease Control and Prevention What You Need to Know About Lassa Fever 2015 http://www.cdc.gov/vhf/lassa/pdf/what-you-need-to-know-about-lassa-factsheet.pdf [accessed 12.02.16]
108. Centers for Disease Control and Prevention SARS Basics Fact Sheet 2012 http://www.cdc.gov/sars/about/fs-sars.html [accessed 12.02.16]
109. World Health Organization Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 2016 http://www.who.int/emergencies/mers-cov/en/ [accessed 12.02.16]
110. World Health Organization Chikungunya Fact Sheet No. 327 2015 http://www.who.int/mediacentre/factsheets/fs327/en/ [accessed 12.02.16]
111. World Health Organization Microcephaly/Zika Virus. Latest Zika Situation Report 2016 http://www.who.int/emergencies/zika-virus/en/ [accessed 12.02.16]